SS18L2

Across TCGA pan-cancer cohorts, SS18L2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SS18L2 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SS18L2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SS18L2 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

GBM and LUAD are the cancer types where SS18L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.688	0.324	.035	2	view →
LUAD	OS	Quartile	All	0.916	0.597	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SS18L2–GBM (OS)

Open the GBM breakdown →